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ABSTRACT
Background NIZ985 is a recombinant heterodimer of
physiologically active interleukin (IL-)15 and IL-15 receptor
alpha. In preclinical models, NIZ985 promotes cytotoxic
lymphocyte proliferation, killing function, and organ/tumor
infiltration, with resultant anticancer effects. In this first-in-
human study, we assessed the safety, pharmacokinetics,
and immune effects of NIZ985 in patients with metastatic
or unresectable solid tumors.
Methods Single agent NIZ985 dose escalation data
are reported from a phase I dose escalation/expansion
study of NIZ985 as monotherapy. Adult patients (N=14)
received 0.25, 0.5, 1, 2 or 4 µg/kg subcutaneous NIZ985
three times weekly (TIW) for the first 2 weeks of each
28-day cycle, in an accelerated 3+3 dose escalation trial
design. IL-15 and endogenous cytokines were monitored
by ELISA and multiplexed electrochemiluminescent
assays. Multiparameter flow cytometry assessed the
frequency, phenotype and proliferation of peripheral blood
mononuclear cells. Preliminary antitumor activity was
assessed by overall response rate (Response Evaluation
Criteria in Solid Tumors V.1.1).
Results As of March 2, 2020, median treatment duration
was 7.5 weeks (range 1.1–77.1). Thirteen patients had
discontinued and one (uveal melanoma) remains on
treatment with stable disease. Best clinical response was
stable disease (3 of 14 patients; 21%). The most frequent
adverse events (AEs) were circular erythematous injection
site reactions (100%), chills (71%), fatigue (57%), and
fever (50%). Treatment-related grade 3/4 AEs occurred
in six participants (43%); treatment-related serious AEs
(SAEs) in three (21%). The per-protocol maximum tolerated
dose was not reached. Pharmacokinetic accumulation of
serum IL-15 in the first week was followed by significantly
lower levels in week 2, likely due to more rapid cytokine
consumption by an expanding lymphocyte pool. NIZ985
treatment was associated with increases in several
cytokines, including interferon (IFN)-γ, IL-18, C-X-C motif
chemokine ligand 10, and tumor necrosis factor-β, plus
significant induction of cytotoxic lymphocyte proliferation

(including natural killer and CD8+ T cells), increased
CD16+ monocytes, and increased CD163+ macrophages at
injection sites.
Conclusions Subcutaneous NIZ985 TIW was generally
well tolerated in patients with advanced cancer and
produced immune activation paralleling preclinical
observations, with induction of IFN-γ and proliferation of
cytotoxic lymphocytes. Due to delayed SAEs at the two
highest dose levels, administration is being changed to
once-weekly in a revised protocol, as monotherapy and
combined with checkpoint inhibitor spartalizumab. These
alterations are expected to maximize the potential of
NIZ985 as a novel immunotherapy.
Trial registration number NCT02452268.

INTRODUCTION
Interleukin (IL)-
15 is a common γ chain
cytokine with a distinctive role in the development, survival, proliferation, and activation of lymphocytes, including natural
killer (NK) cells, canonical αβTCR+CD8+,
γδTCR+, NKT, and intraepithelial T lymphocytes.1 IL-15 shares a common gamma chain
receptor with IL-2, the prototypical immunotherapeutic oncology agent,2 and has similar
biological effects. However, key differences in
production, receptor affinity and secretion
confer unique properties to IL-15, and advantages over IL-2 for the treatment of cancer.
Specifically, endogenous IL-
2 stimulates T
cell activity but subsequently protects against
the risk of autoimmunity by eliminating self-
reactive T cells through a combination of
T-regulatory (Treg) cell maintenance and the
promotion of activation-
induced cell death
(AICD), particularly at low cytokine concentrations.2–4 On the other hand, high-
dose
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IL-2 therapy is associated with severe toxicities including
hypotension, renal failure and capillary leak syndrome.5
These detrimental factors have suggested a need for cytokine therapies possessing the immunostimulatory effects
of IL-2, but with fewer adverse effects.
In contrast to IL-2, IL-15 has been shown to inhibit IL-2
mediated AICD in transgenic mice6 and not lead to Treg
expansion,7 while maintaining the ability to augment cytotoxic immune response. Given the more favorable immunologic profile of IL-15, we and others have explored its
potential as an immunostimulatory cytokine for the treatment of cancer.8
IL-15 is co-expressed with an IL-15 binding protein,
IL-15 receptor alpha (IL-15Rα), a membrane anchored,
stabilizing polypeptide crucial to the natural biosynthesis
of the cytokine.9–12 The two polypeptide chains form
a complex in the endoplasmic reticulum, and undergo
glycosylation and traffic through the Golgi to the plasma
membrane.13–15 The membrane-
anchored IL-
15Rα is
responsible for IL-15 retention on the cell surface, where it
is trans-presented to adjacent responding cells expressing
the IL-2/IL-15 βγ receptor.16 In addition, after a specific
proteolytic cleavage of IL-15Rα,17 a soluble heterodimeric
form of IL-15:IL-15Rα is released, circulates in the blood,
and is biologically active.13 17 18 Thus, although IL-15Rα
was hypothesized to be part of the IL-2/IL-15 receptor
βγ complex by analogy to IL-2Rα, it is instead part of the
physiological cytokine, produced as heterodimeric IL-15,
either cell-associated or soluble.
To leverage the advantageous features of IL-
15, we
produced a recombinant heterodimeric IL-15 molecule
(hetIL-15) with high homology to the naturally produced
IL-15 that circulates in human plasma.17 Administration
of the recombinant heterodimer produced in human
cells has been well tolerated and bioactive across a wide
range of doses in mice and macaques, leading to expansion and tissue trafficking of cytotoxic lymphocytes.17 19–21
While having similar in vitro effects to recombinant
single-chain monomeric IL-15 produced in bacteria, the
heterodimer presents significant advantages in vivo, with
several studies in mice and macaques showing superior
pharmacokinetics (PK) and a 10-fold to 100-fold increase
in agonistic activity over single-chain IL-15.13 17 20 22–24
Extensive studies in murine preclinical models have
demonstrated the efficacy of monomeric or heterodimeric IL-15 to treat cancers. IL-15 enhanced the in vivo
antitumor activity of tumor-reactive CD8+ T cells25 26 and
prolonged the survival of mice in several tumor models
including colon carcinoma, prostatic cancer, melanoma,
breast, myeloma and pancreatic models.22 24 27–33 Recent
studies have investigated the mechanism by which IL-15
induces lymphocyte entry into tumors and increases their
cytotoxicity.27
Different IL-
15 formulations have been tested in
several cancer clinical trials. Single-chain recombinant
IL-15 has been tested in humans as intravenous bolus
(30 min infusion),34 35 subcutaneous (SC) injection35 36
and continuous intravenous infusion.37 In these studies,
2

similar to preclinical models, IL-15 was shown to affect
lymphocyte homeostasis through both redistribution and
proliferation of target cells. However, the administration
of recombinant single-
chain IL-
15 as a bolus resulted
in significant toxicities including fever, chills and blood
pressure changes occurring 2–4 hours after treatment.
Pharmacokinetics revealed that serum concentrations of
IL-15 peaked in a similar time frame, and subsequently
dropped in a rapid fashion. In contrast, another clinically
tested formulation of IL-15 in association with IL-15Rα
fused to the Fc domain of immunoglobulin G (ALT-
803) showed more prolonged cytokine serum levels and
appeared to be better tolerated.38 39 ALT-
803 has also
been tested as an intravenous infusion and SC injection
in patients with advanced solid tumors38 or with relapsed
hematologic malignancy following allogeneic hematopoietic stem cell transplantation.39
In this study, we report on the safety and preliminary activity of the recombinant, heterodimeric form of
IL-15:IL-15Rα (NIZ985/hetIL-15) in patients with metastatic or unresectable solid tumors in a phase I first-in-
human dose escalating study of NIZ985 as a single agent.
MATERIALS AND METHODS
Clinical study design and objectives
This is an open-
label, phase I dose escalation/expansion study initially evaluating the safety and efficacy of
NIZ985 administered by SC injection three times weekly
(TIW) as a single agent for two consecutive weeks of a
4-
week treatment cycle, in patients with metastatic or
unresectable cancers. Subsequent protocol amendments introduced assessments of combination therapy
with the anti-programmed cell death protein 1 (PD-1)
monoclonal antibody spartalizumab, and an alternative
once-weekly NIZ985 administration schedule. Herein are
reported data from the original NIZ985 single agent TIW
dose escalation design.
Dose escalation initially followed an accelerated design
with single patient cohorts until a grade 2 adverse event
(AE) occurred, when cohort size was switched to the
standard 3+3 patient phase I design. Treatment was
continued in the absence of dose-limiting toxicity (DLT)
or other unacceptable AE, disease progression (assessed
radiographically every other cycle), or patient withdrawal.
Patient enrollment commenced in July 2015 and 14
patients were treated at a total of five clinical sites.
The primary objective of the study was to assess the
safety, toxicity profile and DLT, and determine the
maximum tolerated dose of SC NIZ985 administered
TIW. Secondary objectives were to determine the PK
profile of NIZ985; to characterize its pharmacodynamic
effects on the percentages and absolute numbers of
circulating lymphocyte subsets; to measure changes in
circulating levels of cytokines; and undertake a preliminary evaluation of antitumor activity by determining the
overall response rate by Response Evaluation Criteria in
Solid Tumors (RECIST) V.1.1 criteria, time to disease
Conlon K, et al. J Immunother Cancer 2021;9:e003388. doi:10.1136/jitc-2021-003388
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PATIENT SELECTION
Eligible patients were adults at least 18 years of age, with
histologically confirmed metastatic or unresectable solid
tumor malignancy and progression on at least one prior
therapy, for whom curative or palliative measures were
non-existent or associated with minimal survival benefit.
Evaluable or measurable disease was required, defined as
at least one lesion accurately measurable in at least one
dimension as being ≥20 mm by conventional techniques
or ≥10 mm by spiral CT. Patients required an Eastern
Cooperative Oncology Group performance status of 0
or 1, and pulmonary function tests (diffusing capacity/
alveolar volume and forced expiratory volume) at least
50% of predicted. Patients also required normal organ
and marrow function, defined as: (1) leukocyte, absolute
neutrophil, and platelet counts per µL of at least 3000,
1500, and 100,000 cells, respectively; (2) alanine and
aspartate aminotransferases no more than 2.5 × the upper
limit of normal (ULN); (3) a total bilirubin level within
normal limits; and (4) either serum creatinine <1.5 ×
ULN or serum creatinine ≥1.5 × ULN with creatinine
clearance ≥60 mL/min/1.75 m2.
Patients could not have primary brain cancers or active
central nervous system metastases, or other types of malignant disease other than those treated in the study, with the
exception of prior malignancies that had been curatively
treated without recurrence for at least 2 years or completely
resected. Furthermore, active known or suspected autoimmune conditions were excluded, with the exception of those
requiring an external trigger, adequately managed conditions associated with prior anti-PD-1 or anti-programmed
cell death ligand 1 (PD-
L1) treatment, or non-
relevant
conditions such as vitiligo or type 1 diabetes. Other intercurrent illnesses that would exclude patients included clinically significant congestive heart disease and arrhythmias,
severe asthma or an absolute requirement for oral corticosteroids (earlier versions of the protocol also excluded
inhalant corticosteroids), active bacterial infections,
documented HIV infection or a positive serology for HIV
disease, and either serologic or PCR evidence of hepatitis
B or C infection. Pregnant female patients were excluded.
Prior IL-15 treatment was an exclusion criterion, as was
any concurrent anticancer therapy apart from bisphosphonates, or hormone therapy for metastatic prostate cancer
which had progressed despite castrate levels of testosterone.
Other previous treatments must have ended more than 4
weeks prior to enrollment—or more than 6 weeks before
first study dose in the case of prior checkpoint inhibitors,
nitrosoureas, or mitomycin C—and patients must have
recovered from prior treatment toxicities (Common Terminology Criteria for Adverse Events grade 0 or 1).
Treatment plan and drug administration
NIZ985 was administered SC on Monday, Wednesday and
Friday for the first 2 weeks of 28-day treatment cycles at
Conlon K, et al. J Immunother Cancer 2021;9:e003388. doi:10.1136/jitc-2021-003388

doses of 0.25, 0.5, 1.0, 2.0 or 4.0 µg/kg. Treatment was
continued in the absence of unacceptable toxicity, progressive disease per RECIST V.1.1, patient or treating physician’s decision to discontinue treatment, or the patient’s
death. While no patient experienced a DLT, three patients
at the two highest dose levels of 2 and 4 µg/kg experienced
serious AEs during cycle 2 of therapy (discussed in safety
results, below), prompting a halt in the dose escalation
and the enrollment of three new patients at 1 µg/kg to
confirm this as a safe and tolerable level for TIW dosing.
The first nine patients enrolled (dose levels 0.25 µg/kg
through 2 µg/kg, including the first three dosed at 1 µg/
kg) were treated at a single center at the National Cancer
Institute, and the remaining five patients (two at 4 µg/
kg and an additional three at 1 µg/kg) were enrolled at
the other four sites. All patients received concomitant
medication consisting of antipyretics, acetaminophen or
non-steroidal anti-inflammatory drugs, anti-emetics, antihistamines and anti-diarrheals either as premedication or
on an as-needed basis as indicated by their tolerance of
the treatment, as well as other supportive medications,
including intravenous fluids and electrolyte or mineral
replacement to address any AEs to improve their toleration of the treatment.
Safety and response assessments
Patients were monitored during treatment with regular
scheduled physical and laboratory examinations to aid
in the assessment of their condition while receiving the
study medications. Patients were seen on each of their
treatment days and once weekly during weeks 3 and 4 of
cycle 1 for physical examination and evaluation of injection site reactions, and had regular chemistry and hematology panels.
Pharmacokinetic, pharmacodynamic, and biomarker analysis
To characterize the PK parameters of NIZ985, blood
samples were collected from all patients at pre-
dose,
throughout the study, and at the end of treatment.
NIZ985 serum concentrations were measured using a
good laboratory practice (GLP)-validated electrochemiluminescent (ECL) immunoassay specific for the NIZ985
heterodimer, with a lower limit of quantitation (LLOQ)
of 50 pg/mL in 100% human serum. NIZ985 PK parameters were derived from concentrations determined with
the GLP assay at recorded sampling times using non-
compartmental methods in Phoenix WinNonlin V.6.2
(Certara USA, Princeton, New Jersey, USA). Derived
parameters included the maximum serum concentration (Cmax), time to Cmax (Tmax), time to last evaluable
measurement (Tlast), concentration at Tlast (Clast), and the
area under the concentration–time curve from 0 to Tlast
(AUClast).
Circulating IL-
15 was also evaluated using a fit-
for-
purpose Meso Scale Discovery (MSD) human V-plex ECL
assay (Meso Scale Diagnostics, Rockville, Maryland, USA)
as supportive surrogate data for NIZ98518 in a post-hoc
exploratory analysis of PK in the first nine patients
3
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treated. This assay, which is reported to recognize IL-15
both as a single-chain molecule and in association with
IL-15Rα, has a lower limit of detection of 1.4 pg/mL and
was performed according to the manufacturer’s instructions; data were reported as equivalent single chain IL-15.
Systemic cytokines and other biomarkers were measured
pretreatment and post-treatment in serum samples using
the MSD V-
PLEX Human Cytokine 30-
plex and MSD
V-
Plex Human Biomarker 54-
plex kits, according to
manufacturer’s instructions.
Patients had flow cytometry assessments for lymphocyte and monocyte cell subsets at baseline and while
on-treatment to follow immune cell population changes.
For the last five patients treated (after the study became
multicenter) flow analyses were performed using the
methodology and antibody panel described in online
supplemental table S1. For the first nine patients treated,
flow cytometry was performed using cryopreserved
longitudinal samples of peripheral blood mononuclear
cells (PBMC). Frozen PBMC were thawed using Thawsome adaptors40 into 9 mL warmed R10, washed with
phosphate-buffered saline, and incubated with 100 µL of
a 1:800 dilution of the viability dye UV Blue (Invitrogen)
for 20 min. After incubation, the cells were washed once
with staining buffer (RPMI 1680 supplemented with
4% heat-
inactivated fetal calf serum) and incubated
with the extracellular antibody cocktails, made with 20×
Super Bright Staining Buffer (eBioscience), for 20 min
at room temperature. After the incubation, the cells
were washed with staining buffer and permeabilized with
FoxP3 Fixation/Permeabilization buffer (eBioscience)

at room temperature for 30 min. Cells were washed with
1× Permeabilization Buffer (eBioscience) and incubated
with 100 µL of the intracellular antibody cocktail, made
in 1× perm buffer, at room temperature for 30 min. Cells
were washed with 1× perm buffer and resuspended in
phosphate-buffered saline . Samples were run on a BD
FACSymphony flow cytometer. Data were analyzed using
the FlowJo software platform. Antibody panel details are
given in online supplemental table S2.

RESULTS
Patient population and treatment
As of March 2, 2020, a total of 14 adult patients with
advanced metastatic cancers were treated in an accelerated dose escalation design with NIZ985 doses of 0.25 µg/
kg (n=1), 0.5 µg/kg (n=2), 1.0 µg/kg (n=6), 2.0 µg/
kg (n=3) and 4.0 µg/kg (n=2). Baseline characteristics
are shown in table 1. Study participants were heavily
pretreated, with 50% having received three or more prior
treatments and nearly two-thirds prior immunotherapy
for a variety of solid tumors, of which only a minority
(3/14) were classical immunosensitive diagnoses of renal
cell carcinoma or melanoma (online supplemental table
S3). By data cut-off (March 2, 2020) 13 participants had
discontinued, primarily for progressive disease (online
supplemental table S4). The median duration of treatment was two cycles, with a range between <1 (three doses;
patient discontinued for a treatment-unrelated AE) to 19
cycles (online supplemental figure S1).

Table 1 Participant demographics
NIZ985
0.25 µg/kg n=1

NIZ985
0.5 µg/kg n=2

NIZ985
1.0 µg/kg n=6

NIZ985
2.0 µg/kg n=3

NIZ985
4.0 µg/kg n=2

All NIZ985
patients N=14

Median age, years
(range)
Age category, n (%)

50 (NA)

62 (59–64)

53 (42–69)

53 (52–73)

63 (58–67)

57 (42–73)

 <50 years

0

0

2 (33.3)

0

0

2 (14.3)

 50 to <65 years

1 (100)

2 (100)

3 (50.0)

2 (66.7)

1 (50.0)

9 (64.3)

 ≥65 years

0

0

1 (16.7)

1 (33.3)

1 (50.0)

3 (21.4)

Characteristic

Sex, n (%)
 Male

1 (100)

1 (50.0)

4 (66.7)

1 (33.3)

1 (50.0)

8 (57.1)

 Female

0

1 (50.0)

2 (33.3)

2 (66.7)

1 (50.0)

6 (42.9)

 Black/African
American

0

0

1 (16.7)

0

0

1 (7.1)

 White

1 (100)

2 (100)

5 (83.3)

2 (66.7)

2 (100)

12 (85.7)

 Unknown

0

0

0

1 (33.3)

0

1 (7.1)

Race, n (%)

Ethnicity, n (%)
 Hispanic/Latino

0

0

1 (16.7)

1 (33.3)

0

2 (14.3)

 Other
 Not reported

1 (100)
0

2 (100)
0

5 (83.3)
0

2 (66.7)
0

1 (50.0)
1 (50.0)

11 (78.6)
1 (7.1)
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Table 2 Treatment-related adverse events and serious adverse events
NIZ985
NIZ985
0.25 µg/kg n=1 0.5 µg/kg n=2

NIZ985
NIZ985
NIZ985
1.0 µg/kg n=6 2.0 µg/kg n=3 4.0 µg/kg n=2

All NIZ98 patients
N=14

Treatment-related events
1 (100)
 Any event

2 (100)

6 (100)

3 (100)

2 (100)

14 (100)

 Grade 3–4 events

1 (50.0)*

2 (33.3)†

1 (33.3)‡

2 (100)§

6 (42.9)

6 (100)

3 (100)

2 (100)

14 (100)

0

 Common treatment-related events (>20% in all patients)
  ISR

1 (100)

2 (100)

  Chills

0

1 (50.0)

4 (66.7)

3 (100)

2 (100)

10 (71.4)

  Fatigue

0

1 (50.0)

4 (66.7)

3 (100)

0

8 (57.1)

  Fever

0

1 (50.0)

4 (66.7)

2 (66.7)

0

7 (50.0)

  Arthralgia

0

2 (100)

2 (33.3)

1 (33.3)

0

5 (35.7)

  Nausea

0

1 (50.0)

2 (33.3)

1 (33.3)

1 (50.0)

5 (35.7)

  Hyperhidrosis

0

0

2 (33.3)

2 (66.7)

0

4 (28.6)

  Decreased appetite 0

0

2 (33.3)

1 (33.3)

0

3 (21.4)

  Constipation

0

0

1 (16.7)

2 (66.7)

0

3 (21.4)

  Cognitive disorder

0

1 (50.0)

1 (16.7)

0

1 (50.0)

3 (21.4)

0

0

0

2 (66.7)

1 (50.0)

3 (21.4)

Serious adverse events
 Any SAE

   Acute kidney Injury 0

0

0

0

1 (50.0)

1 (7.1)

  Oliguria

0

0

0

1 (50.0)

1 (7.1)

0

  Dermatitis bullous

0

0

0

1 (33.3)

0

1 (7.1)

  Purpura

0

0

0

1 (33.3)

0

1 (7.1)

  Embolism
  Vasculitis

0
0

0
0

0
0

0
0

1 (50.0)
1 (50.0)

1 (7.1)
1 (7.1)

*Grade 3 anemia.
†Grade 3 ISR (misclassified; subsequently reviewed and reclassified as grade 2) and grade 3 diarrhea.
‡Grade 3 increase in international normalized ratio.
§Grade 3 hyponatremia (one patient); grade 3 lymphocyte count decreases (two events), peripheral edema, purpura, and oliguria, plus grade
3 and 4 events of embolism, acute kidney injury, and vasculitis (one patient).
ISR, injection site reaction; SAE, serious adverse event.

Safety
NIZ985 treatment was generally well tolerated, particularly at the initial dose levels. Table 2 summarizes
treatment-related AEs and serious AEs (SAEs) regardless of study drug relationship, and online supplemental
table S5 summarizes all AEs. Injection site reactions
(see below), chills, fatigue, and fever were the most
related events, along with characcommon treatment-
related events like anorexia, followed
teristic cytokine-
by arthralgias, hyperhidrosis and gastrointestinal events
that occurred in about 25% of the patients. There was no
clear relationship between the frequency or severity of
these AEs and the dose level. Grade 3 or 4 AEs occurred
in six patients overall at rates of approximately 30%–50%
in the three intermediate dose levels (0.5–2 µg/kg) and
in both of the 4 µg/kg patients (online supplemental
table S5). Treatment-related grade 3 or 4 AEs were dissimilar among these six patients (table 2), and most unrelated grade 3 or 4 AEs were attributable to tumor pain
or chronic organ/system dysfunction due to underlying
Conlon K, et al. J Immunother Cancer 2021;9:e003388. doi:10.1136/jitc-2021-003388

disease or prior treatment. With the exception of one
patient, the circular, erythema multiforme-
like injection site reactions (ISRs) were not problematic in terms
of pain, edema or size. ISRs increased with increasing
dose, and patients treated at higher doses developed
more notably visible circular areas of erythema and mild
tenderness beginning at the site of their treatment injection within 24–48 hours of injection. These continued
to enlarge circumferentially and occasionally reached
30 cm in diameter, but most often did not require
analgesics. Clearance occurred circumferentially from
the center, often resulting in a bullseye appearance of
erythema (online supplemental figure S2). Of note, ISR
weal size was observed to diminish with each subsequent
cycle. Pathologic and immunohistochemical analyses of
these injection site reactions showed perivascular infiltrate of CD3+ CD4+ lymphocytes, and CD56+ lymphocyte
infiltration at the dermal–epidermal junction as well as
increased number of CD3+CD8+ lymphocytes and monocyte/macrophages in the tissue (figure 1).
5
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Figure 1 NIZ985 injection site reaction is characterized by local immune cell infiltration. Micrographs from skin biopsy of
patient treated with 2 μg/kg NIZ985. (A) H&E stain demonstrated subacute spongiotic dermatitis with superficial perivascular
inflammation. (B–E) Immunohistochemistry micrographs for immune cell markers. (B) CD3+ cells (T cells) and (C) CD8+ cells
were primarily found near dermal blood vessels (black arrows). (D) CD56+ cells were also found near the dermal/epidermal
junction, while (E) CD163+ cells (monocyte lineage) were prominent throughout the affected dermis.

There were three medically significant SAEs (table 2)
that occurred during the second cycle of treatment
in patients receiving 2 and 4 µg/kg. The first 2 µg/kg
patient developed new diffuse vesicles soon after the day
12 injection that subsequently progressed to widespread
multiple painful bullae. The patient began treatment
with systemic corticosteroids and required 40 days of
treatment for resolution of lesions. Pathologic examination confirmed the diagnosis of immunoglobulin A (IgA)
bullous dermatitis or pemphigoid. The second 2 µg/kg
patient developed purpuric lesions largely on the lower
extremities during the last week of cycle 2 associated with
fatigue, fevers and arthralgias, with the purpura caused by
supratherapeutic INR in the setting of warfarin treatment
for prior pulmonary embolus. Biopsy showed a mild perivascular lymphocytic infiltrate with no vasculitis, and the
event was ultimately attributed to excess anticoagulation,
which resolved after interruption of warfarin and administration of fresh frozen plasma and vitamin K. The third
SAE occurred in a 4 µg/kg patient who presented with
6

symptoms of dehydration and tachycardia following the
fourth dose of cycle 2. A CT pulmonary angiogram showed
bilateral pulmonary emboli and the patient was admitted
to hospital for anticoagulation and clinical management.
On the second day of admission, the patient developed
lower extremity purpuric lesions. Immunofluorescent
biopsy of the left thigh and left forearm demonstrated
IgA vasculitis, and the patient received 8 days of prednisone 40 mg/day before tapering off corticosteroid treatment. The patient further developed non-
obstructive
acute kidney injury requiring a dialysis treatment. The
patient’s condition improved, however they were lost
to follow-up following transition to hospice care due to
disease progression.
Preliminary efficacy
There were no complete or partial responses observed,
and the best response of stable disease (SD) in three
participants (21%) did not appear to be dose-dependent
(online supplemental figure S3). Nine patients
Conlon K, et al. J Immunother Cancer 2021;9:e003388. doi:10.1136/jitc-2021-003388
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Table 3 NIZ985 pharmacokinetic parameters
Participant

Dose (µg/kg)

Cmax (pg/mL)

Tmax (hr)

1
2

1
1

132
120

24.0
27.4

3

2

185

23.0

4
5

2
4

138
461

12.0
7.17

AUClast (pg·h/mL)

Clast (pg/mL)

Tlast (h)

4085
2838

52.6
120

44.4
27.4

5126

56.1

46.1

3975
10 910

60.3
70.3

43.0
49.1

NIZ985 concentrations in the 0.25 ug/kg and 0.5 ug/kg TIW cohorts were below the assay LLOQ (50 pg/mL). In these two cohorts, samples
were analyzed beyond the current demonstrated stability period of 710 days. Hence, measurements from these cohorts were not reported.
AUClast, area under the NIZ985 concentration–time curve from 0 to Tlast; Clast, last quantifiable NIZ985 serum concentration; Cmax, maximum
NIZ985 serum concentration; Tlast, time post-dose of Clast; Tmax, time post-dose of Cmax.

discontinued for confirmed disease progression and
three for AEs, one of which (small bowel obstruction) was
determined to be due to disease progression during the
first week of treatment. As seen in online supplemental
figure S3, three participants had dramatic enlargement of
their tumor burden and the remaining 10 with available
data had mostly minor changes in their target lesions.
Of the three participants achieving SD, one (metastatic
renal cell carcinoma) had an SD duration of 28 days, one
(cholangiocarcinoma) withdrew consent after 1 day of
SD, and, of note, one has had prolonged disease stabilization for over 15 months at cut-off with metastatic uveal
melanoma, a diagnosis normally associated with variable
response to therapy and a poor outcome. This patient
remains on treatment at time of writing.
Pharmacokinetic data
Due to a high number of samples below the NIZ985
heterodimer-
specific ECL assay LLOQ, consistent
concentration–time data and derived PK parameters were
only available for five patients in the 1–4 µg/kg dosing
groups (table 3). Tmax was highly variable (7–27 hours)
and both Cmax and AUClast appeared similar among

patients receiving 1 or 2 µg/kg but were higher for the
patient administered 4 µg/kg. Due to the limited number
of evaluable PK samples and low numbers of patients,
dose proportionality could not be assessed. Supportive
post-hoc analyses of serum IL-15 in the first eight patients
treated at doses between 0.25 and 2 µg/kg, using the
Mesoscale ECL assay with a lower detection limit, also
showed comparable concentration–time profiles at cycle
1, day 1 for patients receiving 1 or 2 µg/kg (figure 2A), as
well as a suggestion of accumulation over the first week
of cycle 1 treatment followed by significantly lower exposures in the second week (figure 2B).
Immunological and biomarker changes in peripheral blood
IL-15 effects on blood leukocytes
Among the first nine patients treated, dose-
related
increases in the expression of Ki67 were observed in
several leukocyte subsets—including CD4+ and CD8+αβ
T lymphocytes, γδ T lymphocytes and NK cells—over
the course of the first 2–3 cycles (figure 3A–D). Similar
increases were observed among the remaining five
patients analyzed separately (online supplemental figure
S4) using the methodology and antibody panel described

Figure 2 Pharmacokinetics and circulating serum IL-15 concentrations during cycle 1 of NIZ985 treatment in a subset of
participants. (A) Serum IL-15 concentration–time profile (mean±SEM) after subcutaneous injection of NIZ985 on cycle 1, day 1.
(B) Pooled analysis of serum IL-15 levels immediately before each injection of NIZ985 (1 and 2 μg/kg groups). Violin plots depict
median, quartiles and range of data. Each data point represents an individual patient sample. Comparison between indicated
time points was by mixed-effects ANOVA. ANOVA, analysis of variance; IL, interleukin.
Conlon K, et al. J Immunother Cancer 2021;9:e003388. doi:10.1136/jitc-2021-003388
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Figure 3 Lymphocyte proliferation is consistently induced during NIZ985 treatment cycles. (A–D) Individual proliferative
responses (percentage Ki67+ cells) induced during each cycle of NIZ985 in circulating CD4+ T cells, CD8+ T cells, γδ T cells, and
NK cells. Insets show mean peak percentage Ki67+ cells by dosing group; (E) Individual percentage CD16+ monocytes (from
total CD14+ monocytes) during each cycle of NIZ985. NK, natural killer.

in online supplemental table S1. Doses of 0.25 or 0.5 µg/
kg NIZ985 evidenced modest post-baseline increases in
Ki67+ cell percentages, whereas higher doses of 1 and
2 µg/kg were associated with greater mean increases in
Ki67+ NK cells (data summarized in online supplemental
table S6).
We also evaluated the levels of absolute lymphocyte
counts after NIZ985 administration. The most consistent
increase in absolute blood counts was in NK cells, which
increased by 1.2-
fold to 4.8-
fold in different patients
(online supplemental figure S5). Despite high levels of
proliferation, we did not observe a consistent increase in
the absolute numbers of circulating CD8+ or CD4+ T cells
(online supplemental figure S5), possibly a result of rapid
migration out of the blood and into effector sites (see also
Discussion). Consistent with the lack of IL-15 receptor
expression, no significant changes were observed in the
frequency or proliferative responses of B lymphocytes
(not shown). Interestingly, although monocytes also do
8

not express the βγ IL-15 receptor, a substantial increase
in the frequency of circulating CD16+ monocytes was
observed in all the analyzed patients (figure 3E). These
data suggest that this effect is indirect, probably through
the induction of chemokines able to mobilize this monocyte subset, which would be in agreement with data
obtained in preclinical animal models.27
Cytokines
NIZ985 treatment was associated with strong induction
in plasma of several cytokines and chemokines including
interferon (IFN)-γ, tumor necrosis factor (TNF)-β, C-reactive protein, C-X-C motif chemokine ligand 10 (CXCL10),
and IL-5, IL-27, and IL-18. Interpretation of these data is
limited by small sample sizes, with generally only one to
three evaluable patients per time point with detectable
levels of analyte in each dosing group. With this caveat,
however, induction appeared to follow one of two patterns
(figure 4A–E), with some cytokine levels showing cyclic
Conlon K, et al. J Immunother Cancer 2021;9:e003388. doi:10.1136/jitc-2021-003388
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Figure 4 (A–E) Mean peak induction (log2-transformed mean ratios of peak-to-baseline levels) of selected plasma cytokines
during cycle 1 dosing; (F) Mean cytokine induction (24–240 hours post-dose) in the pooled 1.0 and 2.0 µg/kg dosing groups.
X-axis: Log2-transformed mean ratios of peak to baseline cytokine levels in both groups; Y-axis: Correlation coefficients of the
mean ratio across all dose groups and NIZ985 dose level. Bars identify regions of high correlation (Pearson’s r ≥0.8 or ≤–0.8)
and high response (≥2-fold). C, cycle; CRP, C-reactive protein; CXCL10, C-X-C motif chemokine ligand 10; D, day; FC, fold-
change; IFN, interferon; IL, interleukin; TNF, tumor necrosis factor.

peaks and others a monotonic rise towards an eventual
plateau. The dose relatedness of induction was variable,
with high correlations between induction and dose noted
for IFN-γ, TNF-β, and IL-27, and lesser correlation for
IL-5, IL-18, C-reactive protein, and CXCL10 (figure 4F).
We also noted the induction of several chemokines able
to recruit monocytes, including IL-
18, macrophage
inflammatory protein (MIP)-
1β/CCL4, MIP-1α/CCL3,
and MIP-3α/CCL20. These chemokines were induced by
2×, 1.5×, 1.5× and 1.4×, respectively.
DISCUSSION
In this study, we present first-in-human data for NIZ985,
a recombinant heterodimeric form of IL-15 and IL-15Rα.
Treatment was generally well tolerated in this highly
refractory set of patients, and produced consistent induction of effector lymphocytes and a preliminary suggestion of clinical activity. Disease stabilization was achieved
Conlon K, et al. J Immunother Cancer 2021;9:e003388. doi:10.1136/jitc-2021-003388

by 3 of the 14 participants (metastatic renal carcinoma,
uveal melanoma, cholangiocarcinoma), consistent with
single-agent data for other IL-15 formulations showing
stable disease to be the best observed response in solid
tumors.34 36–38
Although protocol-defined dose-limiting toxicities were
not observed, significant systemic immune-related events
occurred during cycle 2 in two patients treated in the 2 µg/
kg and 4 µg/kg dosing cohorts. Since both were IgA antibody mediated, their immunopathophysiology is difficult
to connect to the known biology of IL-15. Bullous skin
disorders characterized by complement and IgG deposition have been previously reported in patients receiving
checkpoint inhibitors,41 as has IgA nephropathy,42 43
suggesting that agents thought to primarily affect cellular
immunity can be associated with antibody-related toxicity.
The two significant immune-related toxicities observed
suggested a less frequent SC injection schedule may be
9
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more advantageous than the TIW schedule explored
here, and this rationale was supported by preliminary
PK data for serum IL-15 in this study suggesting a similar
persistence and accumulation of exogenous heterodimer
as previously noted in macaques.20 Once-weekly administration of NIZ985 is currently under evaluation under a
revised study protocol. Other than these SAEs, the safety
profile and tolerability of NIZ985 in this trial was good
and would be expected to be similar or better on a once-
weekly schedule.
NIZ985 AUC and Cmax were broadly similar at 1 and
2 µg/kg dosing using the validated NIZ985 heterodimer-
specific ECL assay, which is likely to represent a combination of assay limitation, interpatient variability, and
paucity of available data. Both parameters were higher in
the single patient dosed at 4 µg/kg for whom data were
available, but further data are required to assess dose
dependency and the exposure–response relationship.
Post-hoc evaluation of serum IL-15 showed favorable
kinetics, without the high serum levels previously associated with toxicity in clinical trials of single-chain IL-15.34–37
Our concentration–time data suggested a potentially
slower elimination rate in humans than the ~12 hour half-
life previously seen for SC heterodimer administration in
macaques.20 The significantly lower steady-state levels of
serum IL-15 during week two of treatment are consistent
with macaque data20 and with the previously observed
expansion of IL-
15 receptor-
bearing lymphocytes on
initial administration of IL-15:IL-15Rα heterodimer that
reduces free serum levels.17 20 21 26 34 This in turn implies a
marked in vivo expansion of effector cells in tissues that is
not easily measured in peripheral blood, probably due to
cell extravasation into effector anatomical sites. If focused
at tumor deposits, such expansion would suggest a potential for clinical activity for NIZ985 in combination with
other therapeutic agents that may surpass single agent
activity.
Pharmacodynamic activity was established for NIZ985
in terms of both lymphocyte expansion and cytokine
induction. Dose-
related, post-
baseline increases in the
proportion of Ki67+ proliferating cells was noted for T cell
subsets and NK cells, similar to previous macaque data,
accompanied at higher doses (1 or 2 µg/kg) by substantive (≥2-fold) increases in NK cell numbers. The increase
in total body lymphocytes is not measured accurately in
blood, because hetIL-15—as well as other formulations of
IL-15 administration—induces relocation of lymphocytes
to the tissues, as shown in macaques and humans.20 34 This
rapid and massive relocation of lymphocytes to effector
sites creates the impression of lymphopenia in peripheral blood. After the termination of dosing, lymphocytes
return gradually to the blood; therefore, measurements
of lymphocytes after the end of the NIZ985 cycle show an
increase. Patients appear to have different rates of expansion and/or return in peripheral blood, which may be
the result of patient history. NK cells behave differently;
they are found increased in the blood of most patients
after 1 week of hetIL-
15 treatment, due probably to
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the rapid mobilization of new NK cells from the bone
marrow. Furthermore, a marked dose-related increase in
the frequency of peripheral CD16+ monocytic cells was
observed despite the absence of an IL-15 receptor target
on these cells. Induction of a number of circulating cytokines and other biomarkers in plasma was observed in
pooled data from the 1 and 2 µg/kg cohorts, with IL-5,
TNF-β, and IFN-γ in particular showing high and strongly
dose-correlated levels of induction, and IL-18, IL-3, C-reactive protein, and CXCL10 showing high but less dose-
correlated induction. Individual cytokines showed either
intermittent peaks of induction after dosing or a steady
rise after the first dose. Although these cytokine data are
limited by small samples, the different patterns of induction suggest the potential involvement of different pharmacodynamic mechanisms.
In addition to these changes in peripheral blood,
immunohistochemical analysis showed immune activation at NIZ985 injection sites that consistently led to a
self-limited injection site reaction characterized by infiltration of leukocytes expressing CD3, CD8, CD56 or
CD163, regardless of the administered dose. The potential for high local concentrations of NIZ985 to recruit T
and NK cells represents a promising characteristic for
future studies of intratumoral or local administration of
this cytokine. Moreover, the observation of monocytic
CD163+ cells throughout the injection-site dermis, along
with the increases noted in peripheral CD16+ monocytes, suggests a cross-talk of NIZ985 effects with antigen
presenting cells, which warrants further investigation.27
Given the general similarity of the observed PK and pharmacodynamic effects of NIZ985 in this clinical study to
previous non-human primate data, it is of interest to note
that a step-
dose regimen of increasing NIZ985 doses in
macaques has been shown to result in more stable cytokine
exposure and downstream proliferation of cytotoxic lymphocytes during the course of the treatment cycle that was not
associated with increased toxicity.20 The results of the step-
dose regimen in macaques also suggest that tachyphylaxis,
a mechanism postulated to explain experimental results
showing that repeated administration of IL-15 resulted in
decreasing effects on circulating blood lymphocytes, as also
suggested in figure 3. However, our results support an alternative explanation for this phenomenon, which explains all
the in vivo observations and our preclinical studies. IL-15 is
a homeostatic cytokine and it exists in equilibrium with the
lymphocytes.44 The predictions of tachyphylaxis were not
fulfilled on administration of increasing doses of IL-15, as in
step-dosing. In many preclinical experiments, we observed
continuous expansion of lymphocytes on increasing doses
of hetIL-15.20 45 This is the prediction of the homeostatic
mechanism. These considerations may be important for the
development of optimal clinical protocols for the use of this
powerful cytokine.
The incrementally decreasing size of ISR weals observed in
this study with increasing duration of exposure to NIZ985 is
also a feature of interest. Both these observations emphasize
the importance of understanding the unique pharmacology
Conlon K, et al. J Immunother Cancer 2021;9:e003388. doi:10.1136/jitc-2021-003388
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of novel immunotherapeutics in order to optimize their clinical use, and suggest that exploration of a step-dose approach
in humans may constitute a way to maximize exposure and
efficacy while minimizing toxicity. However, the safety and
efficacy of such an approach in oncotherapy remains to be
tested.
These data therefore demonstrate NIZ985 to be a bioactive human cytokine causing systemic immune changes
potentially favorable for the treatment of cancer.46–48 RECIST-
defined objective responses were not observed in this patient
group, similar to clinical testing of other IL-15 formulations
across the spectrum of administration routes and schedules.34 36–38 In contrast, a trial of ALT-803 for patients with
hematologic malignancies who had relapsed after allogeneic
stem cell transplant showed an objective response rate of
19%,39 suggesting possible synergy of IL-15 formulations with
the underlying graft-versus-leukemia capacity in these transplant patients. The disparity between the preclinical efficacy
observed for IL-15 and clinical responses obtained to date
implies that a deeper understanding of IL-15 pharmacology
and activity is necessary for optimal use. The immunologic
effects of NIZ985 could potentially augment the anticancer
efficacy of other immunotherapeutic options such as cancer
vaccines or checkpoint inhibitors, or other modalities like
chemotherapeutics or radiotherapy. The potential for treatment synergy between NIZ985 and checkpoint inhibitors is
currently under preliminary evaluation with the anti-
PD1
antibody spartalizumab under a protocol amendment to the
current study. The strong effects of hetIL-15 on dendritic
cell accumulation in tumors of preclinical models27 suggest
the use of hetIL-15 in combinations aiming to induce tumor
antigen presentation and immunotherapeutic response. In
addition, the known effects of hetIL-15 on metastatic disease
suggest its use in efforts to reduce metastatic dissemination
and burden.
Different forms of IL-15 and mimetics such as IL-2/anti-
IL-2R antibody complexes have been proposed and tested
alone and in combination with other agents—checkpoint
inhibitors, monoclonal antibodies and chimeric antigen
receptor T cells—both in preclinical mouse models and in
clinical trials. Combination therapies have the advantage
of targeting multiple mechanisms to enhance the immune
response against tumors (for reviews see 8 49 50). Combination of NIZ985 with spartalizumab has been initiated in
Japan in patients with advanced solid tumors and lymphoma
(NCT04261439). Additionally, several phase I trials include
the use of IL-15 with nivolumab (anti-PD-1) and ipilimumab
(anti-cytotoxic T-lymphocyte associated protein 4 [CTLA4])
in refractory cancers (NCT03388632), with avelumab (anti-
PD-L1) in T cell malignancies (NCT03905135), with obinutuzumab (anti-
CD20) in chronic lymphocytic leukemia
(NCT03759184), and with alemtuzumab (anti-
CD52) in
adult T-cell leukemia (NCT02689453). The results from the
phase I trial of the heterodimeric molecule N-803 delivered
subcutaneously in combination with nivolumab in patients
with metastatic non-small cell lung cancer have been recently
reported.51 Another promising combination strategy is the
use of N-803 together with bi/tri-specific antibodies (BiKE
Conlon K, et al. J Immunother Cancer 2021;9:e003388. doi:10.1136/jitc-2021-003388

and TriKE). BiKE and TriKE consist of the single-chain variable fragments against both NK activating receptors and
tumor associated antigen(s), such as CD19, CD20 and CD33,
linked to human IL-15.52 53
In conclusion, these promising first-in-human data point to
NIZ985 as an immunotherapeutic suitable for further clinical
evaluation to optimize its dosing schedule and use in combination regimens, in order to leverage fully the potentially
favorable immunologic changes observed during treatment.
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Table S1. Novartis flow cytometry methods and panel details.
The following panel and methodology were used to assess the last five patients treated, following
study expansion to a multicenter trial.
Fluorochrome

Marker

Manufacturer

Catalog #

Clone

BUV395
BUV737
BV421
eF506

CD45
CD4
CD8
Viability
TIM-3
CD25
CD45RA
CD335
HLA-DR
CD3
CD159a
TCR Vδ2
CD3
CCR7
CD56
LAG-3
NKG2D
PD-1
CD14
Ki-67
CD16
CD38

BD
BD
BD
ThermoFisher
BD
BD
BD
BD
BD
ThermoFisher
Miltenyi Biotec
Biolegend
ThermoFisher
BD
BD
ThermoFisher
BD
BD
Biolegend
BD
ThermoFisher
ThermoFisher

563792
612748
562428
65-0866-14
565564
563719
563733
563043
564041
11-0036-42
130-113-565
331424
45-0036-42
560765
340363
61-2239-42
562498
561272
325618
558615
47-0168-42
47-0389-42

HI30
SK3
RPA-T8
N/A
7D3
M-A251
HI100
NKp46
G46-6
SK7
REA110
B6
SK7
150503
NCAM16.2
3DS223H
1D11
EH12.1
HCD14
B56
eBioCB16
HIT2

BV650
BV711
BV786
FITC
PerCP-Cy5.5
PE
PE-eF610/
PE-CF594
PE-Cy7
Alexa Fluor 647
APC-eF780

•

•

Methodology

•

Briefly, up to 4x106 cryopreserved PBMCs were thawed quickly in a 37ºC
water bath and washed by centrifugation with pre-warmed RPMI medium
containing 10% FBS. After washing, cells were stained with fixable viability
dye eFluor™506 (ThermoFisher, San Diego, CA) at a dilution of 1:100 in
wash buffer (phosphate-buffered saline containing 0.1% sodium azide and
2% fetal bovine serum) followed by staining with fluorochrome-conjugated
surface antibodies for 30 minutes at room temperature in the dark. Previously
prepared and qualified antibody cocktails consisting of 12 surface antibodies
were utilized.
After incubation, cells were washed once by centrifugation in wash buffer
and fixed with 1x Fixation/Permeabilization Buffer from the
Foxp3/Transcription Factor Staining Buffer Set (ThermoFisher, San Diego,
CA) for 30 minutes at room temperature in the dark. After fixation, cells were
washed once by centrifugation with 1x Permeabilization Buffer from the
Foxp3/Transcription Factor Staining Buffer Set and resuspended in 1x
Permeabilization Buffer. Fluorochrome-conjugated intracellular antibody (Ki67) was added and cells were incubated for 30 minutes at room temperature
in the dark. Cells were then washed twice by centrifugation with 1x
Permeabilization Buffer and resuspended in 0.5% Formalin solution.
Cells were then acquired on a BD LSRFortessa X-20 equipped with 5 lasers
(BD Biosciences, San Jose, CA) and data was analyzed using FlowJo
software (FlowJo LLC, Ashland, OR). For data analysis of the T-cellProliferation assay, after exclusion of debris, doublets and dead cells, T cells
were further gated for CD4+ and CD8+ subsets. Both CD4+ and CD8+ T
cells were then subsequently analyzed for the expression of various
biomarkers to define proliferating (Ki-67), checkpoint inhibitor-expressing
(PD-1, LAG-3, TIM-3), activated (CD38, HLA-DR) and memory (CCR7,
CD45RA) T cell subsets. For data analysis of the NK-cell-Proliferation
assay, after exclusion of debris, doublets and dead cells, NK cells were
further gated for NK subsets (CD56, CD16), as well as inhibition (CD159a)
and activation (CD25, CD335, NKG2D) biomarkers. Monocytes were also
assessed for CD14, CD16 and HLA-DR expression.
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Table S2. NCI flow cytometry panel details.
The following monoclonal antibodies were used for the flow analyses in the first nine patients treated in the study: from BD
Biosciences: CXCR5-BUV395 (clone RF8B2), CD16-BUV496 (clone 3G8), CD14-BUV805 (clone M5E2), FoxP3-BV450
(clone 236A/E7), CD28-BV480 (clone L293), CD4-BV750 (clone SK3), CD45RA-BB700 (clone 5H9), CD279-PECF594
(clone EH12.1), CD152-PECy5 (clone BNI3), CD25-PECy7 (clone M-A251), Ki-67-Ax647 (clone B56), Granzyme BAx700 (clone GB11), CD20-BUV395 (clone 2H7), CD56-BV510 (clone NCAM16.2), CD94-BV786 (clone HP-3D9) and
CD3 custom conjugated with BB660 (cloneSP34-2). From BioLegend: CD8-BV570 (clone RPA-T8), CD127-BV605 (clone
A019D5), CCR6-BV650 (clone G034E2), Vd2-BV711 (clone B6), CCR7-BV785 (clone G043H7), Granzyme A-PE (clone
CB9), CXCR3-APCCy7 (clone G025H7), CD80-BV421 (clone 2D10), HLA-DR-BV570 (clone L243), CD303-BV605
(clone 201A), CD11c-BV650 (clone 3.9) and CD86-BV711 (clone IT2.2). From ThermoFisher: Vd1-FITC (clone TS8.2).
From Beckman Coulter: NKG2a-PECy7 (clone Z199). The CD11b antibody (clone ICRF44) was conjugated in-house with
FITC. The viability dye (LIVE/DEAD fixable Blue dead cell stain) was from Invitrogen. Two different staining cocktails
were used (T cell panel, NK and myeloid panel) as indicated below.
T cell panel
Detector
UV395
UV450
UV500
UV795
V440
V510
V570
V605
V650
V710
V750
V800
B515
B660
B710
G575
G610
G660
G780
R660
R710
R780

Marker
CXCR5
LIVE/DEAD fixable Blue Dead Cell Stain
CD16
CD14
FoxP3
CD28
CD8
CD127
CCR6
V delta 2
CD4
CCR7
V delta 1
CD3
CD45RA
Gran A
CD279/PD-1
CD152
CD25
Ki-67
Granzyme B
CXCR3

Clone

Fluor

Source

RF8B2

BUV395

3G8
M5E2
236A/E7
L293
RPA-T8
A019D5
G034E2
B6
SK3
G043H7
TS8.2
SP34-2
5H9
CB9
EH12.1
BNI3
M-A25I
B56
GB11
G025H7

BUV496
BUV805
BV450
BV480
BV570
BV605
BV650
BV711
BV750
BV785
FITC
BB660
BB700
PE
CF594PE
Cy5PE
Cy7-PE
Ax647
Ax700
Cy7APC

BD
Invitrogen
BD
BD
BD
BD
BioLegend
BioLegend
BioLegend
BioLegend
BD
BioLegend
Thermo
Custom (BD)
BD
Biolegend
BD
BD
BD
BD
BD
BioLegend

Clone

Fluor

Source

2H7

BUV395

3G8
M5E2
2D10
NCAM16.2
L243
201A

BUV496
BUV805
BV421
BV510
BV570
BV605

BD
Invitrogen
BD
BD
Biolegend
BD
Biolegend
Biolegend

NK and myeloid panel
Detector
UV395
UV450
UV500
UV795
V440
V510
V570
V605

Marker
CD20
LIVE/DEAD fixable Blue Dead Cell Stain
CD16
CD14
CD80
CD56
HLA-DR
CD303

V650

CD11c

3.9

BV650

Biolegend

V710
V750
V800

CD86
CD4
CD94

IT2.2
SK3
HP-3D9

BV711
BV750
BV786

B515

CD11b

ICRF44

FITC

B660
G575
G610

CD3
Gran A
CD279/PD-1

SP34-2
CB9
EH12.1

BB660
PE
CF594PE

G780

NKG2a

Z199

Cy7PE

R660
R710

Ki-67
Granzyme B

B56
GB11

Ax647
Ax700

Biolegend
BD
BD
VRC
conjugate
Custom (BD)
Biolegend
BD
Beckman
Coulter
BD
BD

Intracellular antibodies are bold and italicized
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Table S3. Prior treatment and disease diagnosis.

Characteristic

NIZ985
0.25 μg/kg
n=1

NIZ985
0.5 μg/kg
n=2

NIZ985
1.0 μg/kg
n=6

NIZ985
2.0 μg/kg
n=3

NIZ985
4.0 μg/kg
n=2

All NIZ985
patients
N=14

Number of prior antineoplastic regimes, n (%)
1

0

0

1 (16.7)

2 (66.7)

0

3 (21.4)

2

0

1 (50.0)

1 (16.7)

1 (33.3)

1 (50.0)

4 (28.6)

≥3

1 (100)

1 (50.0)

4 (66.7)

0

1 (50.0)

7 (50.0)

10 (71.4)

Prior medication, n (%)
Chemotherapy

1 (100)

1 (50.0)

4 (66.7)

3 (100)

1 (50.0)

Hormonal therapy

0

1 (50.0)

0

0

0

1 (7.1)

Immunotherapy

0

2 (100)

3 (50.0)

2 (66.7)

2 (100)

9 (64.3)

Anti-CTLA4

0

1 (50.0)

2 (33.3)

0

0

3 (21.4)

Anti-PD-1

0

2 (100)

3 (50.0)

0

1 (50.0)

6 (42.9)

Targeted therapy

0

0

0

0

1 (50.0)

1 (7.1)

Vaccine

0

0

1(16.7)

0

0

1 (7.1)

Other

0

0

3 (50.0)

0

0

3 (21.4)

Breast cancer

0

0

1 (16.7)

0

0

1 (7.1)

Cholangiocarcinoma

0

0

0

1 (33.3)

0

1 (7.1)

Colorectal cancer

0

0

1 (16.7)

1 (33.3)

0

2 (14.3)

Cutaneous melanoma

0

1 (50.0)

1 (16.7)

0

0

2 (14.3)

Disease diagnosis, n (%)

Metastatic renal cell carcinoma

1 (100)

0

0

0

0

1 (7.1)

Neuroendocrine

0

0

0

0

1 (50.0)

1 (7.1)

Renal carcinoma

0

0

0

0

1 (50.0)

1 (7.1)

Thyroid cancer

0

0

1 (16.7)

0

0

1 (7.1)

Uveal melanoma

0

0

1 (16.7)

0

0

1 (7.1)

Leiomyosarcoma

0

1 (50.0)

0

0

0

1 (7.1)

Osteosarcoma

0

0

1 (16.7)

0

0

1 (7.1)

Carcinoma ex pleomorphic
adenoma

0

0

0

1 (33.3)

0

1 (7.1)

CTLA4, cytotoxic T-lymphocyte-associated protein 4; PD-1, programmed cell death-1.
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Table S4. Patient outcomes.
NIZ985
NIZ985
0.25 μg/kg 0.5 μg/kg
n=1
n=2
Treatment ongoing, n (%)
End of treatment, n (%)
Disease progression
Adverse event
Physician decision
Participant withdrawal

0
1 (100)
1 (100)
0
0
0

0
2 (100)
1 (50.0)
1 (50.0)
0
0

NIZ985
1.0 μg/kg
n=6

NIZ985
2.0 μg/kg
n=3

1 (16.7)
5 (83.3)
4 (66.7)
0
0
1 (16.7)

0
3 (100)
2 (66.7)
1 (33.3)
0
0

NIZ985 All NIZ985
4.0 μg/kg patients
n=2
N=14
0
2 (100)
0
1 (50.0)
1 (50.0)
0

1 (7.1)
13 (92.9)
8 (57.1)
3 (21.4)
1 (7.1)
1 (7.1)
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Table S5. Summary of adverse events (all grades) irrespective of relationship to study
treatment.
NIZ985
0.25 μg/kg
n=1

NIZ985
0.5 μg/kg
n=2

NIZ98 1.0
μg/kg
n=6

NIZ985
2.0 μg/kg
n=3

NIZ985
4.0 μg/kg
n=2

All NIZ985
patients
N=14

Any event
Grade 3–4

1 (100)
0

2 (100)
1 (50.0)*

6 (100)
2 (33.3)†

3 (100)
1 (33.3)§

2 (100)
2 (100)‡

14 (100)
6 (42.9)

ISR

1 (100)

2 (100)

6 (100)

3 (100)

2 (100)

14 (100)

Chills

0

1 (50.0)

4 (66.7)

3 (100)

2 (100)

10 (71.4)

Fatigue

0

1 (50.0)

4 (66.7)

3 (100)

1 (50.0)

9 (64.3)

Pyrexia

0

1 (50.0)

4 (66.7)

2 (66.7)

0

7 (50.0)

Constipation

0

0

2 (33.3)

2 (66.7)

1 (50.0)

5 (35.7)

Nausea

0

1 (50.0)

2 (33.3)

1 (33.3)

1 (50.0)

5 (35.7)

Arthralgia

0

2 (100)

2 (33.3)

1 (33.3)

0

5 (35.7)

Decreased appetite

0

0

2 (33.3)

1 (33.3)

1 (50.0)

4 (28.6)

Hyperhidrosis

0

0

2 (33.3)

2 (66.7)

0

4 (28.6)

Anemia

0

1 (50.0)

1 (16.7)

1 (33.3)

0

3 (21.4)

Diarrhea

1 (100)

0

1 (16.7)

0

1 (50.0)

3 (21.4)

Vomiting

0

0

2 (33.3)

1 (33.3)

0

3 (21.4)

Back pain

1 (100)

1 (50.0)

0

0

1 (50.0)

3 (21.4)

Myalgia

0

1 (50.0)

2 (33.3)

0

0

3 (21.4)

Cognitive disorder

0

1 (50.0)

1 (16.7)

0

1 (50.0)

3 (21.4)

Dyspnea

0

0

1 (16.7)

1 (33.3)

1 (50.0)

3 (21.4)

Hypotension

0

0

0

2 (66.7)

1 (50.0)

3 (21.4)

Pruritus

0

0

1 (16.7)

1 (33.3)

1 (50.0)

3 (21.4)

Adverse event, n (%)

Common adverse events (>20% in all patients)

*Grade 3 events of anemia, small intestinal obstruction, and cellulitis.
†
Grade 3 events of ISR (subsequently reclassified as grade 2 on review), hyperglycemia (3 events), non-cardiac chest pain,
and increased international normalized ratio in one patient, and grade 3 diarrhea in one patient.
§

Grade 3 increase in international normalized ratio.

‡

Grade 3 hyponatremia in one patient; grade 3 and/or 4 events of lymphocyte count decreased (2 events), productive cough,
dysphonia, dysphagia, stridor, bronchial obstruction, tracheal stenosis, esophageal stenosis, esophageal pain, decreased
appetite, dehydration, hypotension, embolism (2 events), atrial fibrillation, fatigue, peripheral edema, purpura, acute kidney
injury, oliguria and vasculitis (2 events) in one patient.
ISR, injection site reaction.
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Table S6. Proportion of lymphocyte subsets expressing Ki67 (Peak fold-change during
treatment over baseline)
Dose

1 µg/kg
(n=6)

2 µg/kg
(n=3)

NK cells

CD8+ T cells

CD4+ T cells

γδ T cells

4.9

4.4

2.1

7.5

11.5

5.5

3.2

29.7

8.2

2.6

5.1

5.1

n.a.

3

3.0

n.a.

8.2

5

2.5

17

n.a.

3.8

4.7

79.3

6.3

5.2

1.2

4.1

5.9

5.4

5

4.1

10.7
11
5.4
15.1
4 µg/kg
2.1
2.0
0.9
3.5
(n=1)
Note: For each patient, fold-change induction of Ki67 expressing cells was determined at
multiple timepoints during Cycle 1 by comparing to pre-treatment baseline value. The
maximum observed increase in Ki67 expression for each patient is reported above. n.a. =
not available.
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Figure S1. Duration of treatment

IO, immuno-oncology; PD, progressive disease; SD, stable disease.
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Figure S3: Best percentage change from baseline in sum of diameters of target lesions.

IO, immuno-oncology treatment; PD, progressive disease; SD, stable disease; UNK, unknown. One patient (1.0 µg/kg) had no
recorded data and is excluded from the plot.
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Figure S4. Individual proportions of Ki67+ CD4+ cells, CD8+ cells,  T cells and NK cells
over the first 2-3 treatment cycles among the last five patients treated in the study.
(see table S1 for methodology).

NK, natural killer.
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